Results 131 to 140 of about 99,253,553 (299)

Cost-effectiveness analysis of oral anti-diabetic medications: DPP-4 inhibitor as monotherapy vs. combination therapy in type 2 diabetic patients in Malang, Indonesia [PDF]

Background: Several anti-diabetic medications are covered under the Indonesian Universal Health Coverage (BPJS). However, metformin is typically prioritized over other options, such as DPP-4 inhibitors, because they are considered costly.
Sidek Ahmad, Zulkhairul Naim, Yurina, Valentina, Che Hasan, Muhammad Kamil, Oktaviana, Prita Aldilla, Triastuti, Efta   +4 more
core   +2 more sources

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

Andrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul, Michal Dubský, Aneta Hujová, Michaela Liegertová   +3 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials

, 2018
Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin glucose-lowering agents, belonging to the incretin family, which are able to improve glycemic control with a favorable safety profile, since they are associated with a ...
Leporini C., Cernaro V., Russo E., De Sarro G., Rivoli L., Bolignano D., Arturi F., Ursini F., di Paola E. D., Coppolino G., Andreucci M., Rivoli Laura, di Paola, E. D., Cernaro, Valeria, di Paola Eugenio Donato, di Paola, Eugenio Donato, Cernaro Valeria, Andreucci Michele, Christian Leporini, Rivoli, Laura, Ursini, Francesco, De Sarro, Giovambattista, Coppolino, G., Giovambattista De Sarro, Arturi, F., Bolignano, Davide, Russo Emilio, De Sarro, G., Francesco Ursini, Laura Rivoli, Coppolino, Giuseppe, Leporini, Christian, Eugenio Donato di Paola, Leporini, C., Giuseppe Coppolino, Michele Andreucci, Arturi, Franco, Ursini Francesco, Bolignano, D., Andreucci, Michele, Russo, E., Ursini, F., Cernaro, V., Russo, Emilio, Bolignano Davide, Arturi Franco, Franco Arturi, Andreucci, M., Coppolino Giuseppe, De Sarro Giovambattista, Leporini Christian, Davide Bolignano, Emilio Russo, Valeria Cernaro, Rivoli, L.   +54 more
core   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice. [PDF]

Biomedicines, 2023
Alshamrani AA, Al-Hamamah MA, Albekairi NA, Attia MSM, Ahmad SF, Assiri MA, Ansari MA, Nadeem A, Bakheet SA, Alanazi WA, Attia SM.   +10 more
europepmc   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

DPP-4 Inhibitor Improved the Cognitive Function in Diabetic Rats. [PDF]

J Healthc Eng, 2022
Hu Y, Wang J, Wang J, Chen W, Zhang Q.
europepmc   +1 more source

Reduction of Angiotensin II Induced Hypertension and Cardiac Fibrosis with GLP-1 Receptor Agonist and DPP-4 Inhibitor via Decreasing NADPH Oxidase Expression

, 2020
This study entails focus on Ang II infused cardiac fibrosis, NADPH oxidases role in the inflammation pathway, and possible treatment options in GLP-1 agonists and DPP-4 ...
Trenton Banks
core  

RS3PE Syndrome with Subsequent PMR Caused by Long-Term DPP-4 Inhibitor Use. [PDF]

Eur J Case Rep Intern Med, 2023
Takahashi Y, Deshpande GA, Kanai Y, Seok Yan K, Naito T.   +4 more
europepmc   +1 more source